SEARCH

SEARCH BY CITATION

References

  • 1
    Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007;62:758766.
  • 2
    Johnston SL. Macrolide antibiotics and asthma treatment. J Allergy Clin Immunol 2006;117:12331236.
  • 3
    Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2012. Available at: http://www.ginasthma.org/.
  • 4
    Louis R, Schleich F, Barnes PJ. Corticosteroids: still at the frontline in asthma treatment? Clin Chest Med 2012;33:531541.
  • 5
    Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 2012; doi:10.1183/09031936.00136712. [Epub ahead of print.]
  • 6
    Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006;61:895902.
  • 7
    Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998;157:18291832.
  • 8
    Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:11391147.
  • 9
    Benden C, Boehler A. Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation 2009;87:15381540.
  • 10
    Yalcin E, Kiper N, Ozcelik U, Dogru D, Firat P, Sahin A et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 2006;31:4955.
  • 11
    Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH. A link between chronic asthma and chronic infection. J Allergy Clin Immunol 2001;107:595601.
  • 12
    Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005;19:CD002997.
  • 13
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:112.
  • 14
    Haynes RB. Conducting Systematic Reviews. In: Haynes RB, Sacket LD, Guyatt HG, Tugwell P, editors. Clinical epidemiology: how to do clinical practice research. Philadelphia, PA: Lippincott Williams & Wilkins, 2006:1542.
  • 15
    Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006;11:193206.
  • 16
    Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820826.
  • 17
    Amayasu H, Yoshida S, Ebana S, Yamamoto Y, Nishikawa T, Shoji T et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000;84:594598.
  • 18
    Black PN, Blasi F, Jenkins CR, Scicchitano R, Mills GD, Rubinfeld AR et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001;164:536541.
  • 19
    Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322329.
  • 20
    Kostadima E, Tsiodras S, Alexopoulos EI, Kaditis AG, Mavrou I, Georgatou N et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004;23:714717.
  • 21
    Piacentini GL, Peroni DG, Bodini A, Pigozzi R, Costella S, Loiacono A et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings 2007;28:194198.
  • 22
    Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148155.
  • 23
    Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010;126:747753.
  • 24
    Kamada AK, Hill MR, Ikle DN, Brenner AM, Szefler SJ. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993;91:873882.
  • 25
    Hahn DL, Grasmick M, Hetzel S, Yale S, Group AS. Azithromycin for bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med 2012;25:442459.
  • 26
    Hahn DL, Plane MB, Mahdi OS, Byrne GI. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 2006;1:e11.
  • 27
    Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002;121:17821788.
  • 28
    Shoji T, Yoshida S, Sakamoto H, Hasegawa H, Nakagawa H, Amayasu H. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999;29:950956.
  • 29
    WHO. Asthma, Fact sheet N 307. 2011. Available at: http://www.who.int/mediacentre/factsheets/fs307/en/index.html.
  • 30
    National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;120:S94S138.
  • 31
    Hanania NA. Targeting airway inflammation in asthma: current and future therapies. Chest 2008;133:989998.
  • 32
    Chipps BE, Zeiger RS, Dorenbaum A, Borish L, Wenzel SE, Miller DP et al. Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort. Curr Respir Care Rep 2012;1:259269.
  • 33
    Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2011;81:6774.
  • 34
    Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010;138:12021212.
  • 35
    Itkin IH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970;45:146162.
  • 36
    Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006;354:15891600.
  • 37
    Strunk RC, Bacharier LB, Phillips BR, Szefler SJ, Zeiger RS, Chinchilli VM et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol 2008;122:11381144. e1134
  • 38
    Gotfried MH, Jung R, Messick CR, Rubinstein I, Garey KW, Rodvold KA et al. Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: a randomized, double-blind, placebo-controlled pilot study. Curr Ther Res Clin Exp 2004;65:112.
  • 39
    Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF Jr, Sorkness CA. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med 2004;170:426432.
  • 40
    van Dalen C, Harding E, Parkin J, Cheng S, Pearce N, Douwes J. Suitability of forced expiratory volume in 1 second/forced vital capacity vs percentage of predicted forced expiratory volume in 1 second for the classification of asthma severity in adolescents. Arch Pediatr Adolesc Med 2008;162:11691174.
  • 41
    Yamaguchi M, Niimi A, Ueda T, Takemura M, Matsuoka H, Jinnai M et al. Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry. Pulm Pharmacol Ther 2009;22:326332.
  • 42
    Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973984.
  • 43
    Brannan JD. Bronchial hyperresponsiveness in the assessment of asthma control: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010;138:11S17S.
  • 44
    Beigelman A, Gunsten S, Mikols CL, Vidavsky I, Cannon CL, Brody SL et al. Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. Chest 2009;136:498506.
  • 45
    Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:18811890.
  • 46
    Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013;368:16651668.
  • 47
    Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127:355360.
  • 48
    Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985993.
  • 49
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.